Cataract

Calcium Fluoride, Tribasic Calcium Phosphate, Causticum, Jacobaea Maritima Whole, Euphrasia Stricta, Sepia Officinalis Juice, Silicon Dioxide


Natural Ophthalmics, Inc
Human Otc Drug
NDC 68770-210
Cataract also known as Calcium Fluoride, Tribasic Calcium Phosphate, Causticum, Jacobaea Maritima Whole, Euphrasia Stricta, Sepia Officinalis Juice, Silicon Dioxide is a human otc drug labeled by 'Natural Ophthalmics, Inc'. National Drug Code (NDC) number for Cataract is 68770-210. This drug is available in dosage form of Pellet. The names of the active, medicinal ingredients in Cataract drug includes Calcium Fluoride - 12 [hp_X]/1 Causticum - 12 [hp_X]/1 Euphrasia Stricta - 7 [hp_X]/1 Jacobaea Maritima Whole - 6 [hp_X]/1 Sepia Officinalis Juice - 7 [hp_X]/1 Silicon Dioxide - 13 [hp_X]/1 Tribasic Calcium Phosphate - 12 [hp_X]/1 . The currest status of Cataract drug is Active.

Drug Information:

Drug NDC: 68770-210
The labeler code and product code segments of the National Drug Code number, separated by a hyphen. Asterisks are no longer used or included within the product code segment to indicate certain configurations of the NDC.
Proprietary Name: Cataract
Also known as the trade name. It is the name of the product chosen by the labeler.
Product Type: Human Otc Drug
Indicates the type of product, such as Human Prescription Drug or Human OTC Drug. This data element corresponds to the “Document Type” of the SPL submission for the listing.
Non Proprietary Name: Calcium Fluoride, Tribasic Calcium Phosphate, Causticum, Jacobaea Maritima Whole, Euphrasia Stricta, Sepia Officinalis Juice, Silicon Dioxide
Also known as the generic name, this is usually the active ingredient(s) of the product.
Labeler Name: Natural Ophthalmics, Inc
Name of Company corresponding to the labeler code segment of the ProductNDC.
Dosage Form: Pellet
The translation of the DosageForm Code submitted by the firm. There is no standard, but values may include terms like `tablet` or `solution for injection`.The complete list of codes and translations can be found www.fda.gov/edrls under Structured Product Labeling Resources.
Status: Active
FDA does not review and approve unfinished products. Therefore, all products in this file are considered unapproved.
Substance Name:CALCIUM FLUORIDE - 12 [hp_X]/1
CAUSTICUM - 12 [hp_X]/1
EUPHRASIA STRICTA - 7 [hp_X]/1
JACOBAEA MARITIMA WHOLE - 6 [hp_X]/1
SEPIA OFFICINALIS JUICE - 7 [hp_X]/1
SILICON DIOXIDE - 13 [hp_X]/1
TRIBASIC CALCIUM PHOSPHATE - 12 [hp_X]/1
This is the active ingredient list. Each ingredient name is the preferred term of the UNII code submitted.
Route Details:ORAL
The translation of the Route Code submitted by the firm, indicating route of administration. The complete list of codes and translations can be found at www.fda.gov/edrls under Structured Product Labeling Resources.

Marketing Information:

An openfda section: An annotation with additional product identifiers, such as NUII and UPC, of the drug product, if available.
Marketing Category: UNAPPROVED HOMEOPATHIC
Product types are broken down into several potential Marketing Categories, such as New Drug Application (NDA), Abbreviated New Drug Application (ANDA), BLA, OTC Monograph, or Unapproved Drug. One and only one Marketing Category may be chosen for a product, not all marketing categories are available to all product types. Currently, only final marketed product categories are included. The complete list of codes and translations can be found at www.fda.gov/edrls under Structured Product Labeling Resources.
Marketing Start Date: 27 Apr, 2022
This is the date that the labeler indicates was the start of its marketing of the drug product.
Marketing End Date: 16 Jan, 2025
This is the date the product will no longer be available on the market. If a product is no longer being manufactured, in most cases, the FDA recommends firms use the expiration date of the last lot produced as the EndMarketingDate, to reflect the potential for drug product to remain available after manufacturing has ceased. Products that are the subject of ongoing manufacturing will not ordinarily have any EndMarketingDate. Products with a value in the EndMarketingDate will be removed from the NDC Directory when the EndMarketingDate is reached.
Listing Expiration Date: 31 Dec, 2023
This is the date when the listing record will expire if not updated or certified by the firm.

OpenFDA Information:

An openfda section: An annotation with additional product identifiers, such as NUII and UPC, of the drug product, if available.
Manufacturer Name:Natural Ophthalmics, Inc
Name of manufacturer or company that makes this drug product, corresponding to the labeler code segment of the NDC.
Original Packager:Yes
Whether or not the drug has been repackaged for distribution.
UNII:O3B55K4YKI
DD5FO1WKFU
C9642I91WL
U4B223LS4X
QDL83WN8C2
ETJ7Z6XBU4
91D9GV0Z28
Unique Ingredient Identifier, which is a non-proprietary, free, unique, unambiguous, non-semantic, alphanumeric identifier based on a substance’s molecular structure and/or descriptive information.

Packaging Information:

Package NDCDescriptionMarketing Start DateMarketing End DateSample Available
68770-210-42600 PELLET in 1 TUBE (68770-210-42)27 Apr, 2022N/ANo
Package NDC number, known as the NDC, identifies the labeler, product, and trade package size. The first segment, the labeler code, is assigned by the FDA. Description tells the size and type of packaging in sentence form. Multilevel packages will have the descriptions concatenated together.

Purpose:


Product Elements:

Cataract calcium fluoride, tribasic calcium phosphate, causticum, jacobaea maritima whole, euphrasia stricta, sepia officinalis juice, silicon dioxide silicon dioxide silicon dioxide euphrasia stricta euphrasia stricta sucrose calcium fluoride fluoride ion jacobaea maritima whole jacobaea maritima whole sepia officinalis juice sepia officinalis juice tribasic calcium phosphate phosphate ion causticum causticum

Indications and Usage:

According to homeopathic indications, these ingredients are intended to stimulate and help the body counteract the symptoms of cataracts.

Warnings:

Warnings: • for oral use only. if you experience eye pain, changes in vision, continued redness or irritation of the eye, or if the condition worsens or persists for more than 72 hours, discontinue use and consult a physician.

Dosage and Administration:

Directions: dissolve three pellets under tongue three times per day or as directed by a medical professional.

Package Label Principal Display Panel:

Label


Comments/ Reviews:

* Data of this site is collected from www.fda.gov. This page is for informational purposes only. Always consult your physician with any questions you may have regarding a medical condition.